Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Getting a diagnosis

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that results in progressive loss of bulbar and limb function. Patients typically die from respiratory failure within 3 years of symptom onset. The incidence of ALS in Europe is 2-3 cases per 100,000 individuals in the general population, and the overall lifetime risk of developing the disease is 1:400. ALS is familial in 5% of cases, and shows a Mendelian pattern of inheritance. ALS is recognized to overlap with frontotemporal dementia. Diagnosis is made on clinical grounds, using internationally recognized consensus criteria, after exclusion of conditions that can mimic ALS. The Revised ALS Functional Rating Scale is currently the most widely used assessment tool; scores are used to predict survival, and have been employed extensively in clinical trials. Riluzole remains the only effective drug, and extends the average survival of patients by 3-6 months. Optimal treatment is based on symptom management and preservation of quality of life, provided in a multidisciplinary setting. The discovery of further effective disease-modifying therapies remains a critical need for patients with this devastating condition.

What this study adds

Evidence grade: Low

This is a narrative review of 100,000 participants. This review covers amyotrophic lateral sclerosis, a neurodegenerative disease with progressive loss of bulbar and limb function, noting that riluzole remains the only effective drug and extends average survival by 3-6 months. It concerns amyotrophic lateral sclerosis diagnosis and management, not Alzheimer's disease treatment, cure or prevention.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Hardiman, O., van den Berg, L. H., & Kiernan, M. C. (2011). Clinical diagnosis and management of amyotrophic lateral sclerosis. Nature reviews. Neurology. https://doi.org/10.1038/nrneurol.2011.153

Vancouver

Hardiman O, van den Berg LH, Kiernan MC. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nature reviews. Neurology. 2011. doi:10.1038/nrneurol.2011.153. PMID: 21989247.

BibTeX

@article{hardiman2011-21989247,
  author  = {Hardiman, O. and van den Berg, L. H. and Kiernan, M. C.},
  title   = {{Clinical diagnosis and management of amyotrophic lateral sclerosis}},
  journal = {Nature reviews. Neurology},
  year    = {2011},
  doi     = {10.1038/nrneurol.2011.153},
  pmid    = {21989247},
  url     = {https://doi.org/10.1038/nrneurol.2011.153}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This review covers amyotrophic lateral sclerosis, a neurodegenerative disease with progressive loss of bulbar and limb function, noting that riluzole remains the only effective drug and extends average survival by 3-6 months. It concerns amyotrophic lateral sclerosis diagnosis and management, not Alzheimer's disease treatment, cure or prevention.

Study details

How this study scored 55/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 3 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 4 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 6 of 7; Citations per year 4 of 5; Impact for its field and year 3 of 6; Cited by studies here 1 of 6; Still being cited 3 of 4; Senior author's track record 4 of 4; Institution's track record 1 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 55 of 100.55 of 100 points earned45 not earned

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Nature reviews. Neurology)
Journal's citation record 3 / 4 Nature Reviews Neurology: journal h-index 269 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2011 — within 20 year(s) of the newest study here
Sample size 4 / 4 100,000 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 6 / 7 Cited 621 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 36.5 citations a year over 17 year(s) since 2011
Impact for its field and year 3 / 6 Cited 3.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 2 other studies in this library
Still being cited 3 / 4 Cited 93 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Matthew C. Kiernan: h-index 105 (OpenAlex, whole career)
Institution's track record 1 / 3 Utrecht University: institution h-index 1,157 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 4 institution(s) in 3 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 21989247)
Free to read 0 / 2 Behind a paywall — scores zero
Total 55 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

2 studies in the alzhub library list this one in their references.

Related studies in Getting a diagnosis from nearby years

Also tagged “lewy”

1,017 studies in the library carry the topic tag “lewy”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,017 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Getting a diagnosis

See all studies in Getting a diagnosis →